Newsletter | August 22, 2023

08.22.23 -- Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke

SPONSOR

FEATURED EDITORIAL

Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke

By Shahid M. Nimjee, MD, Ph.D., FAANS, FAHA, The Ohio State University Medical Center and Basking Biosciences

Developing new treatments for acute ischemic stroke that can quickly and safely intervene at the right place and time has been a challenging endeavor. Today, the situation is changing due to technological developments related to stroke and recent advances in RNA-based medicines.

INDUSTRY INSIGHTS

Align CMC Strategy With Clinical Path Requirements And Timelines

Article | By Lee Allen and Megan Mason, Lonza

Manufacturers must understand the challenges associated with creating a CMC strategy, and the expertise and resources needed to execute it, in today’s crowded and diverse market.

The Development, Scale-Up, And Manufacturing Of Semi-Solid Dosage Forms

White Paper | Cambrex

Topical products, whether prescription dermatological drugs or over-the-counter lotions, creams, or gels, present unique challenges in terms of development and manufacturing.

Environmental Sustainability: Wastewater Incineration Reduction

Webinar | Lonza

Discover an approach to wastewater treatment that reduces the environmental impact of small molecules production and introduces advanced treatment methodologies to avoid wastewater incineration.

Solving The Analytics Bottleneck In Cell Line Development

Webinar | Sartorius

Discover a fully automated, benchtop, walk-away system for accelerated and efficient cell culture sample preparation. Learn how this system clarifies and purifies mAbs in one step without sacrificing quality.

MOST POPULAR NEWS

•

CAS And Molecule.one Announce A Strategic Collaboration To Accelerate Drug Discovery

•

Parexel & Partex Announce Innovative Alliance Leveraging Artificial Intelligence & Big Data

•

Fluree Announces Partnership With Vitality TechNet

•

Artiva Biotherapeutics Announces FDA Clearance Of IND For AlloNK

•

FDA Accepts MyMD Pharmaceuticals’ IND For Phase 2 Study Of Oral TNF-α Inhibitor MYMD-1

•